Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA

BACKGROUND: Results from the phase III trial CLEOPATRA in human epidermal growth factor receptor 2-positive first-line metastatic breast cancer demonstrated significant improvements in progression-free and overall survival with pertuzumab, trastuzumab, and docetaxel over placebo, trastuzumab, and do...

Descripción completa

Detalles Bibliográficos
Autores principales: Swain, S. M., Baselga, J., Miles, D., Im, Y.-H., Quah, C., Lee, L. F., Cortés, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037862/
https://www.ncbi.nlm.nih.gov/pubmed/24685829
http://dx.doi.org/10.1093/annonc/mdu133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037862/
https://www.ncbi.nlm.nih.gov/pubmed/24685829
http://dx.doi.org/10.1093/annonc/mdu133

Ejemplares similares